Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON REQUEST
Research Comparison

5-Amino-1MQ vs Cagrilintide

5-Amino-1MQ and Cagrilintide are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Metabolic
ClassSmall-molecule NNMT inhibitor (methylquinolinium salt) — not a peptideLipidated 37-residue amylin analogue, Cys2–Cys7 disulfide, C-terminal prolinamide
Molecular weightNot specifiedNot specified
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥99%≥99%
Research areasMetabolic, Cellular LongevityMetabolic
Primary diluentBacteriostatic water (0.9% benzyl alcohol)Bacteriostatic water (0.9% benzyl alcohol)
Working windowCommonly worked with for several weeks at 2-8 °C in preserved diluent.Commonly worked with for 3–4 weeks at 2–8 °C.
Lead degradation routeMicrobial growth in non-preserved diluent — a container problem rather than a molecular one.Fibrillation — the failure mode specific to this molecular class, and the one its whole design addresses.
Freeze–thawTolerant of freeze-thaw — there is no tertiary structure to lose. Aliquoting is still good practice to limit repeated exposure of the stock.Avoid freezing reconstituted material. For an amylin analogue the freeze–thaw concern is not only interfacial aggregation but nucleation of the fibril pathway the molecule was engineered to resist — and fibril formation, once seeded, does not reverse on rewarming.
Light sensitivityNo specific light requirement beyond normal practice.No specific light requirement beyond normal practice.

How they actually differ

Comparing the two: 5-Amino-1MQ is small-molecule nnmt inhibitor (methylquinolinium salt) — not a peptide, while Cagrilintide is lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide — different molecular classes with different handling consequences; their leading degradation routes differ (microbial growth in non-preserved diluent for 5-Amino-1MQ, fibrillation for Cagrilintide), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

5-Amino-1MQ — origin

5-Amino-1MQ is a small quinolinium molecule characterised as a first-in-class inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme studied at the intersection of adipocyte metabolism and the cellular NAD+/methylation pool. It is not an amino-acid chain, which is why it sits apart from every peptide in this catalogue.

Cagrilintide — origin

Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.

5-Amino-1MQ research themes

NNMT inhibition

The defining mechanism — preclinical work has examined how blocking NNMT shifts methylation flux and NAD+ salvage in metabolic tissue models.

Adipocyte energy metabolism

Studied in fat-cell models for effects on cellular energy handling and lipid metabolism.

NAD+ economy

Because NNMT consumes a methyl group tied to the NAD+ precursor pool, it is studied alongside the wider NAD+ research field.

Cagrilintide research themes

Amylin receptor pharmacology

Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.

Amyloid-resistant peptide design

A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.

Protraction by acylation

The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.

Combination with incretin agonists

The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.

5-Amino-1MQ handling

  • Let the sealed vial reach room temperature before opening so moisture does not condense onto the powder.
  • For cell-based assays, prepare a concentrated DMSO stock and dilute into aqueous buffer rather than dissolving directly at high concentration in medium.
  • Label aliquots with reconstitution date and diluent.

Cagrilintide handling

  • Never shake. Swirl gently and allow the cake to dissolve in its own time.
  • Do not freeze reconstituted solution.
  • Add diluent down the vial wall rather than directly onto the cake.
  • Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.

Both third-party tested

Every Popular Peptides batch of 5-Amino-1MQ and Cagrilintide is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

5-Amino-1MQ reference

Full 5-Amino-1MQ reference 5-Amino-1MQ storage 5-Amino-1MQ reconstitution 5-Amino-1MQ calculator5-Amino-1MQ product details

Cagrilintide reference

Full Cagrilintide reference Cagrilintide storage Cagrilintide reconstitution Cagrilintide calculatorCagrilintide product details

Related comparisons

5-Amino-1MQ vs CJC-1295 (No DAC)5-Amino-1MQ vs CJC-1295 + Ipamorelin5-Amino-1MQ vs DSIP5-Amino-1MQ vs Epithalon5-Amino-1MQ vs GLOW5-Amino-1MQ vs GLP-2/Tirz5-Amino-1MQ vs GLP-3/RT5-Amino-1MQ vs IGF-1 LR3

5-Amino-1MQ and Cagrilintide are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.